Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) fell 2.6% on Wednesday . The stock traded as low as $10.07 and last traded at $10.07. 359 shares were traded during mid-day trading, a decline of 91% from the average session volume of 3,781 shares. The stock had previously closed at $10.34.
Innovent Biologics Stock Up 12.9%
The company has a fifty day moving average price of $10.69 and a two-hundred day moving average price of $10.86.
Innovent Biologics Company Profile
Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.
The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).
Recommended Stories
- Five stocks we like better than Innovent Biologics
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
